| 摘要 |
2067738 9203148 PCTABS00010 Non-insulin dependent, or type 2, diabetes mellitus is treated by administration of a hypoglycemic agent that enhances plasma concentrations of amylin and of an amylin antagonist. The hypoglycemic agent can be a sulfonurea or a biguanide. The amylin antagonist can be an amylin or a calcitonin gene-related peptide having altered reactive sites or being cross-linked or truncated. Patients are also monitored for enhanced plasma concentrations of amylin following administration of hypoglycemic agents, and the effects of agents on the secretion of amylin in biological system such as a cell culture of islet beta cells is monitored by an assay.
|
